News

Gilead Sciences is collaborating with Chinese, US, and global health officials in order to investigate the safety and efficacy of their investigational antiviral compound remdesivir against the novel coronavirus.

There have been more than 19 million cases of influenza recorded in the United States over the 2019-20 flu season.

A study and commentary in The Lancet highlight unique challenges posed by controlled-release drugs.

In Medicaid data spanning a decade, more than a quarter of prescriptions were not associated with a clinician visit.

The US Food and Drug Administration has authorized the use of a new diagnostic for 2019 novel coronavirus.

Multiple blood cultures with appropriate volume can improve diagnosis and treatment of children with suspected sepsis or serious bacterial infection, according to a study at Children’s Hospital Colorado.

A retrospective study evaluated patients with cUTIs who received an outpatient prescription for multiple doses of fosfomycin between July 1999 and June 2018.

New research finds a small fraction of group A streptococcus strains are showing mutations that could lead to lower antibiotic susceptibility, and possibly someday resistance.

The US Centers for Disease Control and Prevention Advisory Committee on Immunization Practices has released the 2020 Recommended Immunization Schedule for adults.

A new study provides evidence that more needs to be done to meet the needs of children in rural Zimbabwe who are exposed to HIV.

Regardless of HIV status, frailty was a strong predictor for mortality and comorbidity for middle-aged adults.

Minimal monitoring of patients receiving sofosbuvir-based therapy for hepatitis C virus resulted in equal cure rates at less cost than standard monitoring, a new study found.

The US Food and Drug Administration has approved Audenz, an adjuvanted influenza A H5N1 monovalent vaccine.

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of January 26, 2020.

We’ve compiled a list of recalls issued by the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) from this past week:

Alex Azar has declared a public health emergency in the United States in response to the 2019 novel coronavirus but says the risk to Americans remains low.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A phase 1 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases will test the safety and effectiveness of monoclonal antibody CIS43LS used as prophylaxis against malaria.

Through the platform providers, consumers, and procurers will have access to full prescribing inserts and FDA-reviewed product labeling which will provide additional important information to patients and providers.

As January comes to an end, we’re looking back at important infectious disease news from the past month.

Newer, more effective antivirals mean hearts from donors with HCV are a viable option for transplantation. Rising opioid-related deaths means there are more of these donors available.

The CDC has also announced the first confirmed non-travel associated case of novel coronavirus in the United States.

According to new data, the prevalence of birth defects potentially related to Zika virus infection increased fourfold from January through March 2017 when compared with January to March 2016.

New research on this resistant organism provides insight on what clinicians may need to account for.

In this episode, our guests compare the West African Ebola outbreak to the ongoing outbreak in the Democratic Republic of the Congo.

The WHO will reconvene on Thursday, January 30, 2020, to discuss whether the novel coronavirus should be designated a public health emergency of international concern.

Agencies such as the CDC have taken principles on-board over the past 10 years, better sharing information on outbreaks in both animals and humans.

This flu season seems to be disproportionately affecting young people as more than 50% of positive influenza test results from public health laboratories have been in individuals under the age of 25 years.

Mosquito-borne viruses can wreak havoc and be exceedingly difficult to track and control. New research suggests one tool to stop outbreaks might be a skin cream that’s already widely available around the world.

Eravacycline is a tetracycline-class antibacterial that was approved for treating complicated intra-abdominal infections in August 2018. What is its place in therapy today?